Yesterday, the SVP of Cel-Sci Corp (CVM), John Cipriano, sold shares of CVM for $69.52K.
Following John Cipriano’s last CVM Sell transaction on August 29, 2019, the stock climbed by 1.1%.
See today’s analyst top recommended stocks >>
Based on Cel-Sci Corp’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $108.9K and GAAP net loss of $12.08 million. In comparison, last year the company earned revenue of $104.2K and had a GAAP net loss of $6.01 million. The Company has a Price to Book ratio of 256.7608. The company has a one-year high of $9.64 and a one-year low of $2.37.
The insider sentiment on Cel-Sci Corp has been negative according to 23 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS).
